Lan P Wei

US Patent:

20030194375, Oct 16, 2003

Filed:

Oct 15, 2002

Appl. No.:

10/272249

Inventors:

Donald Weaver - Halifax, CA
Christopher Tan - North York, CA
Stephen Kim - Kingston, CA
Xianqi Kong - Dollard-des-Ormeaux, CA
Lan Wei - Edison NJ, US
John Carran - Kingston, CA

Assignee:

Queen's University at Kingston and Neurochem, Inc.

International Classification:

A61K049/00
G06G007/48
G06G007/58
A61K031/195
A61K031/198
A61K031/165

US Classification:

424/009200, 703/011000, 514/567000, 514/620000, 514/564000

Abstract:

Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and/or epileptogenesis. Methods for preparing the compounds of the invention are also described.

US Patent:

20080021009, Jan 24, 2008

Filed:

Apr 29, 2005

Appl. No.:

11/587605

Inventors:

Jinyou Xu - Scotch Plains NJ, US
Lan Wei - Edison NJ, US
Anthony Mastracchio - Hoboken NJ, US
Scott Edmondson - Clark NJ, US

International Classification:

A61K 31/4245
A61K 31/397
A61K 31/4525
A61K 31/454
A61P 3/10
C07D 271/07
C07D 413/08

US Classification:

514210200, 514326000, 514364000, 546209000, 548131000

Abstract:

The present invention is directed to novel 1,2,4-oxadiazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

20120108595, May 3, 2012

Filed:

Jun 28, 2010

Appl. No.:

13/382469

Inventors:

Anthony Ogawa - Mountainside NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Lin Chu - Scotch Plains NJ, US
Bing Li - Towaco NJ, US
Lan Wei - Edison NJ, US
Jinyou Xu - Scotch Plains NJ, US
Hyun Ok - Colonia NJ, US
Aaron Lackner - Berkley CA, US
Ihor Kopka - Warren NJ, US

International Classification:

A61K 31/4196
C07D 471/04
C07D 249/08
C07D 401/12
C07D 403/12
C07D 405/12
C07D 487/04
C07F 5/04
A61K 31/4245
A61K 31/437
A61K 31/4439
A61K 31/506
A61K 31/422
A61K 31/519
A61K 31/497
A61P 9/10
A61P 29/00
A61P 19/02
A61P 11/06
A61P 1/04
A61P 1/00
A61P 17/06
C07D 413/12

US Classification:

514248, 548131, 546121, 5482622, 5462724, 544331, 5482662, 548249, 544281, 544236, 548110, 514364, 514300, 514383, 514340, 514275, 514378, 51425931, 51425505

Abstract:

Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.

US Patent:

20120277240, Nov 1, 2012

Filed:

Feb 17, 2011

Appl. No.:

13/520653

Inventors:

Robert R. Wilkening - Maplewood NJ, US
James M. Apgar - Highland Park NJ, US
Tesfaye Biftu - Freehold NJ, US
Danqing Feng - Green Brook NJ, US
Xiaoxia Qian - New York NY, US
Lan Wei - Edison NJ, US

International Classification:

A61K 31/519
C07D 498/04
C07D 409/04
A61K 31/4162
A61K 31/424
A61K 31/404
A61K 31/4985
A61K 31/4188
A61P 3/10
A61P 3/06
A61P 3/04
A61P 9/10
A61P 1/02
A61P 29/00
A61P 1/18
A61P 25/28
A61P 9/00
A61P 37/06
A61P 31/18
A61P 35/04
A61P 15/16
A61P 19/10
A61P 25/22
A61P 5/28
A61P 13/12
A61P 7/00
A61P 5/00
A61P 27/02
A61P 37/00
A61P 9/08
C07D 487/04

US Classification:

514249, 5483605, 548218, 548465, 544280, 544279, 544350, 514406, 514407, 514375, 514414, 5142651, 5142641, 5483031, 514393

Abstract:

The present invention is directed to novel substituted aminotetrahydrothiopyrans and derivatives thereof of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

20130123237, May 16, 2013

Filed:

Feb 23, 2012

Appl. No.:

13/812536

Inventors:

Rajan Anand - Fanwood NJ, US
James M. Apgar - Highland Park NJ, US
Tesfaye Biftu - Freehold NJ, US
Ping Chen - Edison NJ, US
Lin Chu - Scotch Plains NJ, US
Vincent J. Colandrea - North Brunswick NJ, US
Guizhen Dong - Dayton NJ, US
James F. Dropinski - Colts Neck NJ, US
Danqing Feng - Green Brook NJ, US
Jacqueline D. Hicks - Scotch Plains NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Alexander J. Kim - Morganville NJ, US
Kenneth J. Leavitt - Plainsboro NJ, US
Bing Li - Towaco NJ, US
Xiaoxia Qian - New York NY, US
Iyassu Sebhat - Jersey City NJ, US
Lan Wei - Berkeley Heights NJ, US
Robert R. Wilkening - Maplewood NJ, US
Zhicai Wu - Montvale NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/5377
A61K 31/437
A61K 31/4985
A61K 31/351
A61K 31/397
A61K 31/4412
C07D 471/04
A61K 31/496

US Classification:

51421021, 546118, 514303, 544362, 51425304, 544127, 5142342

Abstract:

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

US Patent:

20220235033, Jul 28, 2022

Filed:

May 26, 2020

Appl. No.:

17/613988

Inventors:

- Rahway NJ, US
John S. Debenham - Scotch Plains NJ, US
Amjad Ali - Freehold NJ, US
Lan Wei - Berkeley Heights NJ, US
Tianying Jian - Westfield NJ, US
Dexi Yang - Livingston NJ, US
Anthony K. Ogawa - San Mateo CA, US
Wenlang Fu - Madison NJ, US
Matthew Lombardo - Flemington NJ, US
Rongze Kuang - Green Brook NJ, US
Meng Yang - Westfield NJ, US
Kenneth Ellsworth - Cranbury NJ, US
Peter Nizner - Fanwood NJ, US
Daniel A. Tatosian - Berkeley Heights NJ, US
Robert R. Wilkening - Maplewood NJ, US
Jun Wang - Avon CT, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 401/14
C07D 405/14
C07D 471/04
C07D 413/14
C07D 417/14

Abstract:

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XI activation inhibitors.

US Patent:

20230018413, Jan 19, 2023

Filed:

Aug 3, 2020

Appl. No.:

17/632065

Inventors:

- Rahway NJ, US
Ping Chen - Edison NJ, US
Dane James Clausen - Rahway NJ, US
Jinsong Hao - Belle Mead NJ, US
Dipannita Kalyani - Union NJ, US
Michael T. Rudd - Collegeville PA, US
Shawn P. Walsh - Bridgewater NJ, US
Lan Wei - Berkeley Heights NJ, US
Dexi Yang - Livingston NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 403/04
C07D 207/14
C07D 401/04
C07D 471/04
C07D 417/04
C07D 413/10
C07D 417/14
C07D 413/04
C07D 409/04
C07D 405/04
C07D 498/04
C07D 491/048

Abstract:

The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

US Patent:

20150218149, Aug 6, 2015

Filed:

Aug 15, 2013

Appl. No.:

14/420024

Inventors:

- Rahway NJ, US
Tesfaye Biftu - Freehold NJ, US
Ping Chen - Edison NJ, US
Danqing Feng - Green Brook NJ, US
Jacqueline D. Hicks - Scotch Plains NJ, US
Ahmet Kekec - Jersey City NJ, US
Kenneth J. Leavitt - Mount Laurel NJ, US
Bing Li - Towaco NJ, US
Iyassu Sebhat - Jersey City NJ, US
Xiaoxia Qian - New York NY, US
Lan Wei - Berkeley Heights NJ, US
Robert R. Wilkening - Maplewood NJ, US
Zhicai Wu - Montvale NJ, US

International Classification:

C07D 417/14
A61K 31/4184
C07D 405/14
A61K 31/4192
C07D 413/14
A61K 31/4985
A61K 31/4196
A61K 31/427
A61K 31/506
A61K 31/366
A61K 31/397
C07D 405/12
A61K 31/5377

Abstract:

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.